Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-004910-16-FR
EUCTR2013-004910-16-FR
Active, not recruiting
Not Applicable

Therapeutic multicentric phase II trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticaria

Centre Hospitalier régional Universitaire de Besançon0 sitesJune 22, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsXOLAIR

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Centre Hospitalier régional Universitaire de Besançon
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 22, 2015
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Centre Hospitalier régional Universitaire de Besançon

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 10
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer. - LANDSCAPE
EUCTR2008-001084-10-FRFNCLCC
Active, not recruiting
Phase 1
Encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain.
EUCTR2018-002530-20-ESGrupo Español Multidisciplinar de Melanoma63
Active, not recruiting
Not Applicable
A phase II, multicentre, clinical study evaluating the safety and efficacy of Treosulfan-based conditioning of allogenic transplantation of haemopoietic stem-cells in patients affected by Thalassemia Major - ND
EUCTR2005-005913-40-ITOSPEDALE POLICLINICO S. MATTEO10
Completed
Phase 2
The safety of Cpn10 in patients with multiple sclerosisMultiple SclerosisNeurological - Multiple sclerosis
ACTRN12606000037505CBio Limited50
Unknown
Phase 2
A Phase II, Multicenter, Clinical Trial to Evaluate The Efficacy and Safety of Bevacizumab in Recurrent Malignant GliomaMalignant glioma
JPRN-jRCT2080220811Chugai Pharmaceutical Co., Ltd.31